Principles: extending the utility of [35S]GTP gamma S binding assays.
about
Airway smooth muscle prostaglandin-EP1 receptors directly modulate beta2-adrenergic receptors within a unique heterodimeric complexIdentification and characterization of a novel lysophosphatidic acid receptor, p2y5/LPA6Tools for GPCR drug discovery.GPCR-induced dissociation of G-protein subunits in early stage signal transduction.Heterotrimeric G protein-dependent WNT-5A signaling to ERK1/2 mediates distinct aspects of microglia proinflammatory transformationHippocampal Gαq/₁₁ but not Gαo-coupled receptors are altered in aging.Identification of novel species-selective agonists of the G-protein-coupled receptor GPR35 that promote recruitment of β-arrestin-2 and activate Gα13.Beta-arrestin-based Bret2 screening assay for the "non"-beta-arrestin binding CB1 receptor.Real-time visualization of heterotrimeric G protein Gq activation in living cellsNeonatal 3,4-methylenedioxymethamphetamine (MDMA) exposure alters neuronal protein kinase A activity, serotonin and dopamine content, and [35S]GTPgammaS binding in adult rats.Synthesis of two fluorescent GTPγS molecules and their biological relevanceThe allosteric vestibule of a seven transmembrane helical receptor controls G-protein couplingThe kappa opioid receptor: from addiction to depression, and back.Targeting GTPases in Parkinson's disease: comparison to the historic path of kinase drug discovery and perspectivesG-protein-coupled receptors in drug discovery: nanosizing using cell-free technologies and molecular biology approaches.Anti-inflammatory lipoxin A4 is an endogenous allosteric enhancer of CB1 cannabinoid receptorα₂-Adrenoceptor functionality in postmortem frontal cortex of depressed suicide victims.Agonists with supraphysiological efficacy at the muscarinic M2 ACh receptor.GTPgammaS incorporation in the rat brain: a study on mu-opioid receptors and CXCR4.A Novel Allosteric Activator of Free Fatty Acid 2 Receptor Displays Unique Gi-functional BiasRegulation of RhoGEF proteins by G12/13-coupled receptors.Use of the GTPγS ([35S]GTPγS and Eu-GTPγS) binding assay for analysis of ligand potency and efficacy at G protein-coupled receptors.Probing heterotrimeric G protein activation: applications to biased ligands.G12/13-dependent signaling of G-protein-coupled receptors: disease context and impact on drug discovery.The A, B, Cs of G-protein-coupled receptor pharmacology in assay development for HTS.A perspective on more effective GPCR-targeted drug discovery efforts.Inhibition of sequestration of human B2 bradykinin receptor by phenylarsine oxide or sucrose allows determination of a receptor affinity shift and ligand dissociation in intact cells.Superagonism at G protein-coupled receptors and beyond.CB1 cannabinoid receptor-mediated increases in cyclic AMP accumulation are correlated with reduced Gi/o function.Present and future approaches to screening of G-protein-coupled receptors.Distinct expression and ligand-binding profiles of two constitutively active GPR17 splice variants.GPR35 as a Novel Therapeutic Target.Functional characterization of two isoforms of the P2Y-like receptor GPR17: [35S]GTPgammaS binding and electrophysiological studies in 1321N1 cells.Activation of Galpha (i) and subsequent uncoupling of receptor-Galpha(i) signaling by Pasteurella multocida toxin.Mutation of tyrosine in the conserved NPXXY sequence leads to constitutive phosphorylation and internalization, but not signaling, of the human B2 bradykinin receptor.Non-equivalence of Key Positively Charged Residues of the Free Fatty Acid 2 Receptor in the Recognition and Function of Agonist Versus Antagonist Ligands.Dynamic monitoring of Gi/o-protein-mediated decreases of intracellular cAMP by FRET-based Epac sensorsCoupling of the human A1 adenosine receptor to different heterotrimeric G proteins: evidence for agonist-specific G protein activation.Mutation of Phe318 within the NPxxY(x)(5,6)F motif in melanin-concentrating hormone receptor 1 results in an efficient signaling activity.Development of time-resolved fluorescent based [EU]-GTP binding assay for selection of human Histamine 3 receptor antagonists/inverse agonist: a potential target for Alzheimer's treatment.
P2860
Q24545426-EC886B20-F6B8-4126-BC21-130E9FCF81E3Q24658261-21FE8473-148C-4661-B45F-3BEF63F8139EQ27007472-4C2D2443-FA58-4811-980F-C874B71D742FQ27863908-4B10CE57-D56D-4293-80A3-8A5646BE4697Q28389097-6C5CF857-04AE-446E-8C4B-CD69CC6E606FQ30541270-F671D735-2696-4949-A1F8-C46F44C482CFQ30990011-E422AF33-EB50-4CF5-AF9D-D451CB28FBE7Q33436593-E42B73C8-0E7C-4A05-BD84-8EACCF0EA7A3Q33914273-94ED5F27-067A-4D8F-90A3-18DBD76AA3E9Q33923867-1469E9EC-B3F8-4ABB-8E2F-6C846D502ECAQ33923978-C0F7DA5D-0F92-4891-8CF1-4FA846BEA0B8Q34297570-3FDFAC3C-C757-4031-832E-73FAE46F62AEQ34650892-4FE4C25F-F5E5-4EEA-8742-2679A6DA0944Q35187475-D6668B42-6C67-4DB2-8CC7-B3B08242DB1AQ36290216-95A3C75D-48C1-408E-A4E5-608A65B46EA3Q36485064-F7D89BC5-DA37-472E-AE0E-4E2EF82BABBAQ36583816-83FCD4E8-D893-43E0-944F-462EB6E5A292Q36836367-5D15AEDF-E4E0-4A93-B02B-4FAD33A3B8F3Q37210259-4DEE4BD9-45FD-4FB0-88E2-19C20B8CDA66Q37227642-185D6F69-5A02-4409-8E71-3FED81227E45Q37395997-8C9A4DFE-6D1D-43E2-AEB7-B690D788569BQ37776003-3FDAAEEA-6693-4B42-AB7C-DA49714086CEQ37974268-70407C25-8B8A-48F6-904F-9A3784B87447Q38089133-FEF5F572-0F2D-4D98-A8DC-55C248D1181BQ38089142-DED87D10-1BF4-491B-8EF1-D5F07A8C2D6AQ38089182-4CC3D147-1840-4698-A64D-B55A565968FAQ38335243-2AE33E2D-3999-479C-BD26-2E09BF9A4051Q38567235-B3B8950C-B222-4B60-95CF-5B2FF012311BQ38777382-71047169-2CAC-4774-A50B-F619F9C7CE23Q39437205-8B87F590-E64D-412B-804B-80D3622D4A47Q39640491-A5B73975-222E-4C6E-9937-4C7349DE42DCQ39799967-844B3177-344D-4AAB-ACE3-173F800474E3Q39822022-F59C0265-E3B2-4DC4-985B-FE187A9EF6AAQ39967830-7DB6EF84-D06B-4935-A0CC-153F292E7097Q40552036-277B3793-6EDE-47FE-B6C4-31B69920A37EQ41449385-8504E023-878F-47B0-A954-72FE0964FC4BQ41855922-9BEB283F-853C-48F6-8409-C0DAB9702D71Q42084998-192E8E34-1F56-42D5-A14E-4B0B44F49FD8Q42393228-9F319AD9-7739-4924-8EC8-5B7EADEC79CAQ42465337-1C7B6301-A263-4C60-B980-3D3D7880C80E
P2860
Principles: extending the utility of [35S]GTP gamma S binding assays.
description
2003 nî lūn-bûn
@nan
2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Principles: extending the utility of [35S]GTP gamma S binding assays.
@ast
Principles: extending the utility of [35S]GTP gamma S binding assays.
@en
type
label
Principles: extending the utility of [35S]GTP gamma S binding assays.
@ast
Principles: extending the utility of [35S]GTP gamma S binding assays.
@en
prefLabel
Principles: extending the utility of [35S]GTP gamma S binding assays.
@ast
Principles: extending the utility of [35S]GTP gamma S binding assays.
@en
P1476
Principles: extending the utility of [35S]GTP gamma S binding assays.
@en
P2093
Graeme Milligan
P356
10.1016/S0165-6147(02)00027-5
P577
2003-02-01T00:00:00Z